Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

Interesting MNTA web-site page, that I haven't seen before -

Revised 2/15/2015


Momenta's Corporate Development team is now turning its focus to building upon the company's existing pipeline of novel drugs, and leveraging the capabilities of its innovative technology through out-licensing and in-licensing opportunities.

If you are interested in pursuing a collaboration opportunity with Momenta Pharmaceuticals, or have a technology you wish to introduce to our team, we welcome you to contact us at [e-mail].

Out-licensing

We are interested in pursuing licensing opportunities with interested parties for pivotal development and commercialization of adomiparin (M118), a novel anticoagulant with the potential to be used in multiple settings including medical management of acute coronary syndromes (ACS), angioplasty, and coronary artery bypass graft surgery (CABG).

In-Licensing

We have an active internal development program; however, we are also interested in in-licensing opportunities that may broaden our analytical tool-set or complement our proprietary pipeline. We are seeking in-licensing opportunities in the disease areas of autoimmune, inflammation, and cancer. We also welcome ideas in other diseases where our analytical and characterization approach could aid in solving a research problem that could ultimately lead to novel drugs for patients in need.

http://www.momentapharma.com/about/business-development.php#